Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 224 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Diuretics Clear all

Conditions: Heart Failure
Interventions: Torsemide, Standard Outpatient Heart Failure Management; Drug · Other
Lead sponsor: New York City Health and Hospitals Corporation; Other
Eligibility: 18 Years to 90 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Uncontrolled Hypertension
Interventions: BAROSTIM NEO System and Medical Management; Device
Lead sponsor: CVRx, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 11
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more

Conditions: Hypertension
Interventions: Renin treatment-guided Therapeutics, Referral Hypertension specialist, Aldosterone Antagonist; Drug · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 8
States / cities: Anderson, South Carolina • Beaufort, South Carolina • Florence, South Carolina + 4 more

Conditions: Sepsis
Interventions: Conservative Fluid Management Strategy; Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Nocturia
Interventions: VA106483; Drug
Lead sponsor: Vantia Ltd; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 19
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 16 more

Conditions: Acute Decompensated Heart Failure
Interventions: Experimental: Placebo, Experimental: Metolazone; Drug
Lead sponsor: Aultman Health Foundation; Other
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Canton, Ohio

Conditions: Cardiovascular Diseases, Heart Diseases, Heart Failure, Congestive
Interventions: Spironolactone, Placebo; Drug
Lead sponsor: Carelon Research; Other
Eligibility: 50 Years and older
Enrollment: 3,445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 155
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 120 more

Conditions: Type 1 Diabetes
Interventions: Acetazolamide; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Ascites, Decompensated Cirrhosis
Interventions: BIV201 continuous infusion; Drug
Lead sponsor: BioVie Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Los Angeles, California • Jacksonville, Florida • Miami, Florida + 7 more

Conditions: Hypertension
Interventions: Darusentan, Darusentan Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 67
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more

Conditions: Burn
Interventions: Tetracycline, Duel Energy X-Ray Absorptiometry (DEXA), Bone Biopsy; Drug · Radiation · Procedure
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 5 Years to 18 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2008
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Patent Ductus Arteriosus
Interventions: Cather closure of patent ductus arteriosus (PDA), Conservative management of patent ductus arteriosus (PDA); Device · Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 14 Days to 28 Days
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Columbus, Ohio • Memphis, Tennessee

Conditions: Healthy Participants
Interventions: BMS-986308, Placebo (for BMS-986308), Furosemide; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Heart Failure, Congestive, Renal Insufficiency
Interventions: KW-3902IV; Drug
Lead sponsor: NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 6
States / cities: San Diego, California • Baltimore, Maryland • Ayer, Massachusetts + 3 more

Conditions: Hypertension in Pregnancy, Postpartum Preeclampsia
Interventions: ACE Inhibitors and Diuretics, NIFEdipine ER; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Kidney Disease
Interventions: Diuretic initiation or augmentation; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Heart Failure
Interventions: BAROSTIM NEO® System, Standard of care medical managment therapy for heart failure; Device · Other
Lead sponsor: CVRx, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 23
States / cities: Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 20 more

Conditions: Heart Failure, Congestive
Interventions: KW-3902IV; Drug
Lead sponsor: NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 10
States / cities: Stanford, California • Washington D.C., District of Columbia • Sarasota, Florida + 7 more

Conditions: Critical Illness, Pediatrics, General Surgery, Fluid Therapy, Wounds and Injuries
Interventions: Balanced crystalloid solution volume administration, Packed Erythrocytes Units, Blood Product Unit volume, Plasma volume, Platelets volume; Other
Lead sponsor: Columbia University; Other
Eligibility: 6 Months to 15 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 4
States / cities: Buffalo, New York • New York, New York • Rochester, New York + 1 more

Conditions: Heart Failure
Interventions: Loop Diuretics vs. loop + thiazide diuretics; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3, Pediatric Kidney Disease
Interventions: Blood pressure, Urine protein; Diagnostic Test
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Year to 17 Years
Enrollment: 20,240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Congestive Heart Failure
Interventions: Treatment of Furosemide + Hydrochlorothiazide, Treatment of Furosemide + Metolazone; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 98 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Cirrhosis, Hepatic Encephalopathy, Ascites, Fatigue
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Urinary Incontinence
Interventions: Academic Detailing, Electronic Clinical Decision Support, APP Co-management, Electronic Referral; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: La Jolla, California • Los Angeles, California • Torrance, California

Search by objective public record fields.

Weight-Based Torsemide Dosing in Subjects With Heart Failure

BAROSTIM NEO Hypertension Pivotal Trial

Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study

A Randomized Controlled Trial of a Conservative Fluid Balance Strategy for Patients With Sepsis and Cardiopulmonary Dysfunction (BALANCE Study)

Efficacy Study of VA106483 in Males With Nocturia.

Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.

Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function

Acetazolamide in Persons With Type 1 Diabetes - Dose Finding

A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites

DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

Bone Disease in Severely Burned Children

Preliminary Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low-weight Infants

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants

Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

Oral Combined Hydrochlorothiazide/Lisinopril Versus Oral Nifedipine for Postpartum Hypertension

Association of Diuretics With Change in Extracellular Volume, Natriuretic Peptides, Symptoms, and Cardiovascular Outcomes in CKD

BAROSTIM® Hope for Heart Failure Study

Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).

Effect of Giving Reduced Fluid in Children After Trauma

Comparing Diuretic Strategies in Hospitalized Heart Failure

Preserving Kidney Function in Children With Chronic Kidney Disease

A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients

The Effect of a Large-volume Paracentesis on Fatigue, Sleep, and Quality of Life in Cirrhosis

A Practice-Based Intervention To Improve Care for a Diverse Population Of Women With Urinary Incontinence